ClinicalTrials.gg
Active, not recruitingNCT04833140Updated Aug 7, 2026

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

A Phase 3 interventional study of Estradiol patch and Placebo in NASH - Nonalcoholic Steatohepatitis, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to female participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Massachusetts General Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital — 2 open to participants now, 3 under way, 1 of them phase 3. Non-alcoholic Fatty Liver Disease · Massachusetts General Hospital.

Enrollment
6th of 15
50 · median 40
Started
2021
with 1 other
Phase 3
Only one
of the 16
Registered
12th of 16
by date

Among the 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is the only one in phase 3, and was the 12th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

2 of the 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 45 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital, or all of them as a file.
02

Study summary

Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite this, the treatment options remain limited. Preclinical and preliminary clinical data suggest that estrogen deficiency plays an important role in the pathology of steatosis, inflammation, and fibrosis in non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD. Post-menopausal women are a growing population with a particularly high risk of NASH due to their lack of estrogen. This study will examine the effect of estradiol on hepatic fat and fibrosis in post-menopausal women with NASH.

03

Conditions studied

  • NASH - Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women 45-70 years old
  • NASH by or NAFLD by imaging within 6 months of screen
  • antibody and surface antigen negative
  • Negative mammogram within 1 year

Exclusion criteria

Exclusion criteria:

  • Heavy alcohol use
  • Use of NASH pharmacotherapies within 12 months of study entry
  • Known cirrhosis, stage 4 fibrosis on , or clinical evidence of cirrhosis or portal hypertension on imaging or exam
  • Participation in NASH clinical trial within 6 months of study entry
  • Chronic use of , methotrexate, amiodarone, or tamoxifen within 6 months of entry
  • Known diagnosis of chronic liver disease other than NAFLD or found on biopsy
  • to liver biopsy including > 1.5, \< 50,000/mL, ascites, chronic anticoagulation (other than aspirin), biliary obstruction, peritonitis, inability to lie supine for 30 minutes
  • \< 10.0 g/dL or \< 60 mL/min
  • Contraindications to estrogen therapy
  • Any vaginal bleeding, including spotting, within the last year
  • Active
  • Severe chronic illness
  • Use of estrogen or progesterone within a year of baseline visit
  • Routine MRI exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clip
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Estradiol

    Estradiol in the form of a transdermal patch 100 mcg daily (Vivelle-Dot generic). Women with an intact uterus will also receive progesterone (100 mg) in the form of a vaginal tablet (Endometrin, Ferring Pharmaceuticals, Inc.) inserted daily for endometrial protection

    Drug: Estradiol patch

  • Placebo comparator
    Placebo

    Placebo patch (containing no estradiol) Women with an intact uterus will also receive vaginal placebo capsules (containing no progesterone)

    Drug: Placebo

Interventions

  • DrugEstradiolStudies of EstradiolEstradiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The patch will provide 100mcg of estradiol daily.

  • DrugPlacebo

    Placebo patch will contain no estradiol.

06

What researchers measure

Primary outcomes

  1. Hepatic fat

    Change in percentage of hepatic fat

    Time frame: 12 months

Secondary outcomes

  1. Hepatic fibrosis

    Decrease in hepatic fibrosis by ≥1 stage

    Time frame: 12 months

  2. Non-alcoholic fatty liver disease activity score

    Change in non-alcoholic fatty liver disease activity score (minimum value: 0; maximum value: 8; lower scores indicate less disease activity) without progression of fibrosis stage

    Time frame: 12 months

  3. Whole liver transcriptome profile

    Change in whole liver transcriptome profile

    Time frame: 12 months

  4. Intrahepatic immune cell profiles

    Change in intrahepatic immune cell profile

    Time frame: 12 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Jul 2027, 67 months after the start.

Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2021
First posted
Apr 6, 2021
StartActual
Dec 2, 2021
Primary completionEst.
Jul 9, 2027
CompletionEst.
Jul 9, 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04833140
Responsible party
Karen Klahr Miller, MD (Chief, Neuroendocrine Unit, Massachusetts General Hospital, Massachusetts General Hospital) — Principal investigator
First posted
Apr 6, 2021
Start date
Dec 2, 2021
Primary completion
Jul 9, 2027 (estimated)
Completion
Jul 9, 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

Karen K. Miller, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion